Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
© John Cairns

The Centre will deliver programmes ranging from world-leading mechanistic science to clinical trials, with the aim of improving the understanding and treatment of blood diseases and disorders, and to deliver the best available care to patients.

The day will start with an introduction to the Centre followed by a series of talks from local, national and international speakers highlighting how haematology is being transformed by combining step changes in science and medicine. We would like all our colleagues on both research and clinical sides to join us including young scientists, trainees, nursing, pharmacy and administrative colleagues.

Please register for the event here. There is a £50 registration which can be paid securely via the University's online shop.

More about Keble College can be found here

The Royal College of Pathologists has approved 8 CPD points for the event.

Advances in Haematology: Bringing cutting edge science to patient care

Meeting Programme

8:30-9:00    Registration and coffee
9:00-9:10    Welcome - Prof. Paresh Vyas (Director of the Oxford Centre of Haematology)
9:10-9.15    Opening Address - Prof. Hugh Watkins (Head of the Radcliffe Department of Medicine)
9.15-9.20    Opening address - Dr Bruno Holthof (CEO of Oxford University Hospitals)


Immunology, Inflammation and Stem Cell transplantation (Chair Prof Adam Mead)

9.20 - 9.45    Prof Irv Weissman - Normal and Neoplastic Stem Cells
9.45 - 10.10    Prof Fiona Powrie - Immune pathways in the intestine in health  and disease
10.10-10.35    Dr Andy Peniket & Prof Charles Craddock - Accelerating improvements in stem cell transplant outcome- a Birmingham/Oxford perspective


Lymphoid Disorders (Chair Dr Graham Collins)

10.55 - 11.20    Prof Jude Fitzgibbon - Follicular Lymphoma, it's not just the t(14;18) anymore
11.20 - 11.45    Dr Karthik Ramasamy & Dr Sarah Gooding - Oxford Myeloma programme: a foundation for science and clinical trials.

Red Cells, Iron and Coagulation (Chair Prof Irene Roberts)

11.45 - 12.10    Prof Doug Higgs - Switching Genes on and off in erythropoiesis

12.10 - 12.35    Prof Stuart Orkin - Reactivation of fetal haemoglobin
12.35 - 13:00    Prof Martina Muckenthaler - Macrophages - between iron metabolism and inflammation

13:00 - 13.25     Prof Mike Laffan - Von Willebrand factor and the circulation


Myeloproliferative Disorders (Chair Prof Andrea Pellagatti)

14.10 - 14.35    Prof Tony Green - Myeloproliferative neoplasms – from pathogensis to personalized predictions
14.35 - 15:00    Dr Beth Psaila - Megakaryocyte and erythroid progenitors in normal human haemopoiesis and in myelofibrosis
15:00 - 15.25    Prof Adam Mead - Single cell analysis of CML stem cells


Normal haemopoiesis and Leukaemia (Chair Prof Marella de Bruijn)

15.50 - 16.15    Prof Claus Nerlov - Advances in Normal haemopoietic stem and progenitor biology
16.15 - 16.40    Dr Cristina Lo Celso - Healthy and malignant haematopoiesis in the bone marrow: dynamic cells in an evolving environment
16.40 - 17.05    Prof Paresh Vyas - Haemopoietic hierarchy in normal human haemopoiesis and in AML
17.05 - 17.30    Dr Lynn Quek - IDH inhibitor therapy in AML - studying clonal structures in stem/progenitor cells: impact of therapy

17.30 - 17:55    Prof Gil McVean - Genomic Analysis of Biomedical Big Data

17:55 - 18:00    Prof Paresh Vyas - Closing remarks

6.00    Drinks Reception



Register here for the meeting

About Us

The Oxford Centre for Haematology is a new initiative spanning the University of Oxford and the Oxford University Hospitals NHS Foundation Trust. It is a virtual centre bringing together researchers and clinicians working in haematology to improve the understanding and treatment of blood diseases and disorders, and to deliver the best available care to patients.



















*This meeting has been supported by Abbvie, Alexion, Bristol-Myers Squibb, Janssen, Novartis, Mallinckrodt and Celgene Ltd and they have not influenced the agenda or the selection of speakers in any way